Q4 EPS Forecast for Kezar Life Sciences Reduced by Analyst

Kezar Life Sciences, Inc. (NASDAQ:KZR) – HC Wainwright cut their Q4 2024 earnings per share estimates for shares of Kezar Life Sciences in a report issued on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($2.59) for the quarter, down from their previous forecast of ($1.70). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($5.17) per share. HC Wainwright also issued estimates for Kezar Life Sciences’ Q1 2025 earnings at ($2.56) EPS, Q2 2025 earnings at ($2.57) EPS, Q3 2025 earnings at ($2.59) EPS, Q4 2025 earnings at ($2.61) EPS and FY2025 earnings at ($10.33) EPS.

Kezar Life Sciences (NASDAQ:KZR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.03) by $0.25.

Several other brokerages have also weighed in on KZR. Wells Fargo & Company cut their price target on Kezar Life Sciences from $20.00 to $11.00 and set an “equal weight” rating for the company in a research note on Thursday, November 14th. William Blair reiterated a “market perform” rating on shares of Kezar Life Sciences in a research note on Wednesday, November 13th.

Kezar Life Sciences Stock Performance

Shares of KZR opened at $6.95 on Wednesday. The stock has a market cap of $50.74 million, a P/E ratio of -0.53 and a beta of 0.25. The stock has a 50-day moving average of $7.65 and a two-hundred day moving average of $6.77. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.65 and a current ratio of 7.65. Kezar Life Sciences has a one year low of $5.20 and a one year high of $11.35.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Kezar Life Sciences by 1.0% during the first quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company’s stock worth $2,790,000 after acquiring an additional 30,740 shares during the period. Acuitas Investments LLC increased its position in shares of Kezar Life Sciences by 42.8% during the second quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock worth $592,000 after acquiring an additional 295,956 shares during the period. Acadian Asset Management LLC increased its position in shares of Kezar Life Sciences by 3.6% during the second quarter. Acadian Asset Management LLC now owns 1,855,194 shares of the company’s stock worth $1,112,000 after acquiring an additional 64,356 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Kezar Life Sciences in the second quarter valued at $63,000. Finally, Mackenzie Financial Corp purchased a new position in Kezar Life Sciences in the second quarter valued at $35,000. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.